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ABSTRACT
Rationale and objectives: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an
increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered
questions concerning the natural history, pathophysiology, genetics and the prognosis of the lung disease
in association with AATD. The European Alpha-1 Clinical Research Collaboration (EARCO) is designed
to bring together researchers from European countries and to create a standardised database for the
follow-up of patients with AATD.
Study design and population: The EARCO Registry is a non-interventional, multicentre, pan-European,
longitudinal observational cohort study enrolling patients with AATD. Data will be collected prospectively
without interference/modification of patient’s management by the study team. The major inclusion
criterion is diagnosed severe AATD, defined by an AAT serum level <11 µM (50 mg·dL−1) and/or a
proteinase inhibitor genotype ZZ, SZ or compound heterozygotes or homozygotes of other rare deficient
variants. Assessments at baseline and during the yearly follow-up visits include lung function testing
(spirometry, body plethysmography and diffusing capacity of the lung), exercise capacity, blood tests and
questionnaires (symptoms, quality of life and physical activity). To ensure correct data collection, there will
be designated investigator staff to document the data in the case report form. All data will be reviewed by
the EARCO database manager.
Summary: The EARCO Registry aims to understand the natural history and prognosis of AATD better
with the goal to create and validate prognostic tools to support medical decision-making.
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Alpha-1 antitrypsin deficiency (AATD) is a common, but under-recognised genetic condition that affects
approximately 1 in 2000 to 1 in 5000 individuals in European countries, and predisposes to early-onset
emphysema and liver disease [1, 2]. AAT is mainly produced in the liver, and its function is to protect
tissues, especially the lung, against proteolytic damage from serine proteinases including neutrophil
elastase [3]. To date, >100 variant alleles of the AAT gene have been described, but the Z allele (p.E366 K,
c.1096G>A, rs28929474) is the most prevalent severe deficiency gene leading to lung and liver disease. The
Z protein forms polymers that remain trapped within the rough endoplasmic reticulum of hepatocytes
leading to reduced levels of AAT in the bloodstream [4]. The liver disease arises secondary to
accumulation of the protein in hepatocytes, whereas the imbalance between low blood and hence tissue
levels of AAT and neutrophil elastase in the lung increases the risk of emphysema [1]. Although
tremendous improvements have been made in the understanding of the pathophysiology of the disease in
recent years, many questions remain unanswered.
The natural history of AATD patients is not well known, and there is a lack of prognostic tools to support
medical decision-making, such as early referral for lung transplantation [5]. Although the vast majority of
patients with severe deficiency share the same genetic disorder (PI*ZZ genotype; PI standing for
proteinase inhibitor), the prevalence and severity of liver and respiratory disease vary markedly. Genetic
and environmental cofactors have been suspected, but few have yet been identified [6, 7].
Augmentation therapy, when assessed using computed tomography (CT) lung densitometry, has been
shown to slow the progression of emphysema significantly [8–10]. However, its impact on forced
expiratory volume in 1 s (FEV1) decline, quality of life and mortality has not been definitively established.
Consequently, the efficacy of augmentation therapy is still debated [11], and the cost of therapy is not
reimbursed in all European countries [12, 13]. Furthermore, most studies on AATD have focused on the
ZZ population, and the impact of other rarer variants on outcomes is largely unknown [14].
The answer to these questions requires the access to large cohorts of patients and cannot be addressed
solely at individual country level. This was the main reason to initiate a European Alpha-1 Clinical
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Research Collaboration (EARCO) [15]. EARCO is an initiative under the umbrella of the European
Respiratory Society (ERS) and its clinical research collaborations, pan-European, multicentre research
networks of different fields of respiratory diseases [16]. The initiative brings together multiple stakeholders
including researchers, healthcare providers, patients and industry with the aim of advancing understanding
through clinical and scientific research and improving the quality of life of patients with the deficiency.
EARCO takes advantage of existing AATD registries that have been developed at the national and
international level. Several countries have established registries in which AATD patients are included and
followed-up with clinical and biological data collected [14, 17–23]. However, these registries differ in terms
of inclusion criteria, data collected and frequency and extent of follow-up. Within EARCO, we will
harmonise the data collection process and assess the quality of the data entered into the database. This
article describes the EARCO registry protocol: a pan-European multicentre observational study in patients
with alpha-1 antitrypsin deficiency.
Study objectives
The study objectives are
• to develop a pan-European, multicentre AATD registry incorporating baseline data from ⩾3000
individuals during the first 3 years of the registry;
• to harmonise the data collection process between existing national registries and to ascertain high
quality of the data by monitoring entered data closely;
• to generate longitudinal long-term, high-quality clinical data covering a pan-European population of
AATD individuals of all age groups and all stages of disease severity;
• to understand the natural history and prognosis of AATD better with the goal to create and validate
prognostic tools to support medical decision-making;
• to investigate the effect of AAT augmentation and other therapies on the progression of emphysema and
to examine their potential impact on clinical and functional outcomes, such as FEV1, quality of life and
mortality in a “real-life” population;
• to learn more about the course of the disease in patients suffering from severe AATD with genotypes
other than PI*ZZ.
Study design
The EARCO Registry is a non-interventional, multicentre, pan-European, prospective, observational cohort
study enrolling patients with AATD, as confirmed by biochemical and genetic data. Study centres are
distributed in >20 European countries (figure 1) and include centres in primary, secondary and tertiary
care, according to national arrangements. Current countries have been selected by personal contacts and
invitations of all steering committee members. We will step up efforts in recruiting more countries
through presentations on congresses, meetings and through the webpage (www.earco.eu). The registry is
open to every clinician who manages AATD patients. Patients will be managed according to their local
procedures and policies and without any clinical intervention from the study team. All patients will
provide written informed consent to participate, and participating investigators will collect data
prospectively. The following domains are covered: demographics, proteinase inhibitor genotype and other
laboratory analyses, comorbidities, lung function, respiratory symptoms, ultrasound-based elastography of
the liver, exacerbations of respiratory disease, quality of life, physical activity, chest CT (as applicable) and
treatment.
The study protocol has received central ethics approval by the research ethics committee of the Vall
d’Hebron University Hospital of Barcelona, Spain (PR(AG)480/2018), and the study database will be
hosted in the Vall d’Hebron Research Institute (Barcelona). The study website is located at www.EARCO.
eu. The registry was developed according to recommendations on the design, implementation, governance
and long-term sustainability of disease registries in the European Union (EU) [24, 25]. We expect to
collect detailed information from ∼1000 patients from ⩾10 countries during the first year after creation of
the registry, expanding to 3000 from >20 countries over the following 2 years.
Population
The study population will consist of individuals with diagnosed severe AATD regardless of the clinical
features and severity. The inclusion criteria are a diagnosis of AATD, defined as AAT serum level <11 µM
(50 mg·dL−1) and/or proteinase inhibitor genotypes ZZ, SZ and compound heterozygotes or homozygotes
of other rare deficient variants. The only exclusion criterion is lack of patient consent. Patients will be
discontinued from the study if the informed consent is withdrawn by the patient or his/her legal
custodian. If a patient withdraws from the study, the investigator will undertake every possible effort to
determine the primary reason for a patient’s withdrawal and record this information on the case report
form (CRF).
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For patients who are lost to follow-up (i.e. those patients whose status is unclear because they fail to
appear for study visits without stating an intention to withdraw), the investigator should show “due
diligence” (if allowed by national ethics committee standards) by documenting in the source documents
steps taken to contact the patient, e.g. dates of telephone calls, registered letters, etc.
Visit schedule and assessments
Written informed consent form will be obtained at the baseline visit. All available information will be
collected according to the CRF. Follow-up visits will be scheduled on a yearly basis (±3 months) and
assessments, as described in the following sections, will be performed and recorded in the CRF ((b)
represents baseline only) (figure 2). Because the registry reflects standard assessments in many different
countries and healthy individuals (fulfilling the inclusion criteria) will be included, only the participant’s
sociodemographics and basic information about the presence/type of lung or liver disease will be
absolutely mandatory. All other assessments are not mandatory, but the data manager will request a
minimal set of clinical data through queries to the investigators.
Patient sociodemographics
The following data will be collected from the patient’s medical history: date of birth (b), sex (b), race and
ethnicity (b), height, weight, smoking history, alcohol consumption, working status (including relevant



























FIGURE 1 European countries in which study centres are located.
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history (i.e. index case versus non-index case), AAT level, phenotype/genotype (b), information about
AATD-related diseases (lung disease, liver disease, vasculitis and other AATD-related diseases).
Respiratory physiology
Spirometry equipment and performance of spirometric testing must conform to American Thoracic
Society (ATS)/ERS standards [26]. Pre- and/or post-bronchodilator spirometry values will be collected at
baseline, but post-bronchodilator values alone will be recorded at follow-up visits. Absolute values will be
recorded, to enable the use of different reference equations to calculate the severity of impairment. In
order to reduce the variability of observations, the same equipment must be used and the same staff
member should evaluate and coach a given patient at each visit throughout the study, where possible.
For body plethysmography and diffusing capacity of the lung for carbon monoxide, international
recommendations will be followed [27]. Arterial blood gas analysis will be measured using a quality
controlled analyser. Measurements from the arterialised ear lobe are also acceptable [28]. The procedure
for measurement of the fraction of exhaled nitric oxide will follow the ERS recommendations [29]
Exercise tests
The 6-min walk test will be performed according to the ATS guideline [30]. The patient’s assessment of
dyspnoea and fatigue will be captured using the Borg CR10 scale both before and after the test.
Cardiopulmonary exercise testing will be performed according to the current recommendations [31].
Screening (diagnosis of AAT deﬁciency)
 AAT serum level <11 µM (50 mg·dL–1)
   and/or
 Proteinase inhibitor genotypes ZZ, SZ and compound
 heterozygotes or homozygotes of other rare deﬁcient
 variants
Annual follow-up (±3 months)
 Repeated assessments (as above)
 Mortality (including cause of death)
Baseline assessments
 Sociodemographics
 Respiratory physiology (spirometry, body 
   plethysmography, BGA, FENO)
 Computed tomography
 Exercise tests (6MWT, CPET)
 Blood tests
 Liver assessments
 Symptoms, QoL, scores (SGRQ, CAT, mMRC, EQ-5D,  
   PAVS, BODE, BODEx)
 Comorbidities
 Exacerbations 
 Treatment (COPD-speciﬁc, comorbidity-associated,  
   AATD-speciﬁc) 
Exclusion
 Patient unwilling/unable
   to participate
FIGURE 2 Baseline and follow-up assessments. Only demographics and information about lung and liver
disease are mandatory. AAT: alpha-1 antitrypsin; BGA: blood gas analysis; FENO: exhaled nitric oxide fraction;
MWT: 6-min walk test; CPET: cardiopulmonary exercise testing; QoL: quality of life; SGRQ: St George’s
Respiratory Question-naire; CAT: COPD Assessment Test; mMRC: modified Medical Research Council
dyspnoea scale; EQ-5D: EuroQoL 5-dimension quality of life questionnaire; PAVS: physical activity vital signs
questionnaire; BODE: body mass index, obstruction, dyspnoea and exercise; BODEx: body mass index,
obstruction, dyspnoea and exacerbations.
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Blood tests
Levels of liver enzymes, haematology values including red blood cells, platelets, leukocytes and white blood
cells distribution, fibrinogen, C-reactive protein and hepatic virus titres will be measured and recorded in
the database.
Additional liver assessments
One of two available ultrasound-based methods, either transient elastography or acoustic radiation force
impulse [32] is recommended to assess early fibrosis of the liver. According to the methodology, the result
will be recorded in kPa or m·s−1.
Patient-reported outcomes: symptoms, quality of life, scores
The commonest relevant respiratory symptoms of dyspnoea, cough and sputum production will be
assessed. When the results of sputum culture are available, the bacterial strains isolated will be recorded.
The CRF will also include fields dedicated to elevated liver enzymes and jaundice.
Several standardised questionnaires related to quality of life, symptoms and physical activity, available in
multiple languages, will be used to collect information on patient-reported outcomes. These questionnaires
will include the COPD assessment test [33], the modified Medical Research Council (mMRC) dyspnoea
scale [34], the EuroQoL 5-dimension (EQ-5D) generic quality-of-life questionnaire [35] and the physical
activity vital sign (PAVS) [36]. In some countries, the St George’s Respiratory Questionnaire will be
collected [37]. Patients will complete the questionnaires when rested and in a quiet area, and will be
allowed to ask questions to obtain the truest or best response. The questionnaires will be collected and
checked for completeness before the patient leaves the centre. Instrument scoring and handling of missing
item data will be conducted in accordance with the user guidelines.
The body mass index, obstruction, dyspnoea and exercise (BODE) and the Body mass index, Obstruction,
Dyspnoea and Exacerbations (BODEx) indices will be calculated automatically from entered and
quality-controlled data [38, 39].
Comorbidities
Information on comorbidities (ischaemic heart disease, heart failure, pulmonary hypertension, peripheral
artery disease, diabetes, arterial hypertension, osteoporosis, lung cancer and others) will be collected
according to available information from the medical records. In some countries, an additional set of
comorbidities will be recorded.
Exacerbations of COPD
An exacerbation is defined as an acute worsening of pre-existing respiratory symptoms that results in
additional therapy [40]. COPD exacerbations are classified as mild or treated with increased use of
short-acting bronchodilators only; moderate or treated with antibiotics and/or systemic corticosteroids; and
severe requiring hospitalisation or visits the emergency room.
The following items will be collected: ambulatory and hospital-based exacerbations during the previous
12 months (total number, requiring systemic steroids, requiring antibiotics requiring new-onset
non-invasive ventilation or intensive care unit admission, and main respiratory symptoms).
Information on treatment
The information collected will include the following items: bronchodilators, inhaled corticosteroids, oral
corticosteroids, theophylline, phosphodiesterase-4 inhibitors, long-term oxygen therapy, long-term
antibiotic treatment, noninvasive ventilation, pulmonary rehabilitation, vaccination, lung volume reduction
and transplantation (lung, liver).
Augmentation therapy
The status of augmentation therapy (start, stop, dose, frequency, name of medication) will be assessed at
baseline and at each follow-up visit.
Discontinuation of follow-up
If a patient is lost to follow-up, the reason for this will be assessed whenever possible. Patients who
undergo lung or liver transplantation will be followed-up further. If a patient dies during follow-up, the
cause of death, according to the treating physician, will be recorded.
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Data review and database management
Data collection
It is the investigator’s responsibility to ensure adequate source documentation for all collected data.
Designated investigator staff will enter the data required by the protocol into the CRFs. Spirometry reports
(including the flow–volume curve) and CT reports may be uploaded after appropriate anonymisation. The
investigator must certify that the data are complete and accurate by entering a password. After review for
completeness, plausibility and correctness (flow–volume curve, assessed in uploaded curves) by the
EARCO database monitor, the data will be locked.
Database management and quality control
It is the EARCO database manager’s responsibility to review the CRF data entered by investigational staff
for completeness and accuracy and instruct the site personnel to make any required corrections or
additions. Queries will be sent to the investigational site. Designated investigator site staff are required to
respond to the query and make any necessary changes to the data.
Discussion
In the last official statement about AATD from the ERS, the development of a European, follow-up
registry (a longitudinal cohort) was identified by healthcare providers and patients as a research priority [12].
Registries have the potential to provide important insights into the natural history of rare diseases where
epidemiological data cannot be derived from small-scale prospective cohort studies [41]. In developing the
EARCO registry, we have followed guidance proposed in the EU and the extensive experience from other
registries in the field of respiratory disease [24, 25, 41, 42]. According to these recommendations, it is
essential to define a minimum required dataset that allows the collection of relevant information and
limits the burden on investigators entering the data. Furthermore, the definitions across participating sites
have to be harmonised to ensure that data are consistent and reliable. We will provide a shared data
collection platform, and standardised definitions will be made available on the website (www.earco.eu) and
upon request to all study sites.
Many different national registries on AATD exist throughout Europe [14, 17–23], but inclusion criteria,
variables collected and level of quality control are different. The EARCO registry will harmonise the
collection of prospective data, and its design will allow the new prospectively recorded data to be linked
with the historical data collected in the different national registries. In order to do that, the EARCO
registry will include the sum of all variables included in all national European registries, but some of them
will only be mandatory for patients in a given country where these variables were collected historically.
With this design, EARCO will consist of a set of common mandatory fields and a series of variables that
will be mandatory at a national level.
The inclusion and exclusion criteria are deliberately broad to allow the inclusion of a large and varied
population representative of “real-life” AATD patients and management across Europe.
As an example of variables to be collected, lung function tests are used in the assessment of the severity,
progression and prognosis of COPD [40]. Most studies of lung function decline in COPD are based on
FEV1, because it shows the least variability. However, the main pathological marker of the progression of
the lung disease of AATD is an increase in the destruction of the lung parenchyma, as shown most
specifically by CT densitometry [8, 43]. However, lung densitometry requires careful standardisation and is
not yet ready for use in routine clinical practice [44–46]. EARCO may therefore represent a platform for
the development of future multicentre studies using CT densitometry to evaluate the evolution of
emphysema in large cohorts of patients with AATD in usual clinical practice [47]. In contrast, other lung
function derived markers that have the potential to reflect the magnitude and evolution of emphysema are
gas transfer and the hallmarks of hyperinflation [48]. Therefore, diffusing capacity of the lung for carbon
monoxide and body plethysmographic measurements are measured routinely in the majority of
participating countries, according to the most recent international recommendations [49–51].
We consider a biobank as an important objective for EARCO. However, in the first step we have to
overcome the legal and organisational hurdles that are associated with an international database. As these
hurdles are even higher for an international biobank we will apply for additional funding in a second step
and try to organise/build a biobank in the future.
The participation of patients, coordinated by the European Lung Foundation and Alpha-1 Global has been
crucial for the development of a CRF that takes into consideration not only physiological variables, but
also the variables that have recognised impact and importance patients. Therefore, the inclusion of
patient-reported outcomes was essential. However, although different patient-reported outcomes have been
used in patients with AATD [52], there has been little formal validation of them in this population. We
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therefore included patient-reported outcomes validated in COPD [53]. The EQ-5D is a simple but effective
standardised instrument designed for use as a measure of health outcome. It provides both a compact
descriptive profile and a single index value that can be used in the clinical and economic evaluation of
health care [35]. The COPD assessment test has been developed as a simpler tool to assess quality of life
and symptom burden in COPD patients specifically [33]. The mMRC is an easy-to-use instrument
designed for the quantification of dyspnoea [54]. The latter two questionnaires are also part of the
multidimensional categories of COPD severity [40]. PAVS is a brief (<30 s) physical activity questionnaire
intended to be administered to patients just as vital signs, and height and weight are measured [55]. PAVS
is intended to assess how much light, moderate or vigorous physical activity a person performs in a typical
week. The assessment facilitates patient counselling about physical activity [56]. Composite scores that
combine different physiological measures are used to assess the severity and prognosis of obstructive lung
disease and liver disease, but the experience in AATD is very limited [57]. We will use the BODE [38] and
BODEx [39] for lung disease and the Fibrosis-4 [57] for liver disease to assess their values in monitoring
and determining long-term prognosis in AATD.
The EARCO registry is not the first European registry in AATD. The Alpha One International Registry
(AIR) group included representatives from 14 European and some non-European countries [58]. AIR was
very successful in collecting baseline data. However, due to limited funding, longitudinal data could not be
collected systematically, and the quality of existing data (completeness and accuracy) may be regarded as
suboptimal. This can be partially explained by the fact that data were not processed centrally for data
clearing and data control [59]. The EARCO registry will collaborate closely with existing national AATD
registries and will harmonise the process of data collection and assess the quality of the data included
prospectively, thus overcoming the limitations present in AIR.
The target sample size is based on experiences with similar projects. A short-term target of 1000 patients
in the first year of the project after database setup has been set. To ascertain representativeness for the
European population we aim to include >3000 patients from ⩾20 European countries by the end of the
third year.
Acknowledging the imminent limitations of a non-interventional cohort study, the EARCO registry itself
will not provide an answer to all the research questions in the field of AATD, but it can be the backbone
of different research initiatives, some of which have already been highlighted [15].
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